Technology Profits Confidential

The world of tech and biotechnology will provide endless opportunity for growth and wealth for investors who know where to look.

Technology Profits Confidential is your one-stop shop for the companies of tomorrow's technology... and how you can profit from them.

Armed Antibody Company Launches New Trial

A little over two years ago, we began following Seattle Genetics. The company owns a technology improving antibody-based therapies. By adding a toxin payload to a cancer-homing antibody with a special chemical linker, Seattle Genetics one-ups the current crop of chemotherapy and antibody therapies in both targeting and lethality. It is a new generation of cancer-fighting technology. Seattle Genetics is the first company to market a cancer therapy using this type of technique, but the company isn't alone. One other, ImmunoGen, is in late stages with its own version of this platform.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

LoginGet Access

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco